Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
Go back to Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.| (NASDAQ: ROIV) | Delayed: 39.77 -0.21 (0.53%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $39.98 | 52 Week High | $ | |||
| Open | $40.11 | 52 Week Low | $ | |||
| Day High | $40.71 | P/E | N/A | |||
| Day Low | $39.72 | EPS | $ | |||
| Volume | 32,200,469 | |||||
| (NASDAQ: ROIVW) | Delayed: 2.75 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.75 | 52 Week High | $ | |||
| Open | $25.55 | 52 Week Low | $ | |||
| Day High | $2.75 | P/E | N/A | |||
| Day Low | $2.75 | EPS | $ | |||
| Volume | 555 | |||||
